The drug contains the active ingredient fulvestrant, which belongs to the group of estrogen blockers. Estrogens are female sex hormones and can, in certain cases, contribute to the growth of breast cancer.
Fulvestrant is used either:
as monotherapy for the treatment of postmenopausal women with a form of breast cancer called estrogen receptor-positive breast cancer that is locally advanced or has spread to other parts of the body (metastasized), or
in combination with palbociclib for the treatment of women with a form of breast cancer called hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that has advanced locally or spread to other parts of the body (metastatic). Premenopausal women are also treated with a medicine called a luteinizing hormone-releasing hormone (LHRH) agonist.
If the drug is used in combination with palbociclib, it is important that you also read the palbociclib package leaflet. If you have any questions about palbociclib, please consult your doctor.

250 mg Fulvestrant
500 mg Benzyl alcohol Excipient (+)
750 mg Benzyl benzoate Excipient (+)
500 mg Ethanol 96% (V/V) Excipient (+)
Refined castor oil Excipient (+)

The medicine must not be used
if you are allergic to fulvestrant or any of the other ingredients of this medicine
if you are pregnant or breastfeeding
if you have serious liver problems